{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:45:41Z","timestamp":1789728341950,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100032720","name":"Immedica Pharma AB","doi-asserted-by":"crossref","award":["Immedica Pharma AB"],"award-info":[{"award-number":["Immedica Pharma AB"]}],"id":[{"id":"10.13039\/100032720","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Urea cycle disorders (UCDs) are rare inherited conditions that disrupt ammonia detoxification, leading to hyperammonaemia and potential neurological harm. In Saudi Arabia, high consanguinity rates increase UCD birth incidence. Traditional nitrogen scavengers - sodium benzoate (NaBz) and sodium phenylbutyrate (NaPBA) - are limited by poor palatability, high sodium burden, and large dosing volumes. Glycerol phenylbutyrate (GPB) offers improved pharmacological and practical properties, including slow intestinal hydrolysis, reduced dosing frequency, absence of sodium and propylene glycol, and better tolerability. This study assessed real-world outcomes of GPB in a paediatric UCD population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective analysis of 37 paediatric patients from three Saudi hospitals. Pre- and post-GPB data were compared for plasma ammonia, hyperammonaemic crises (HACs), HAC-related hospitalisations and durations, growth z-scores, and adverse events. A caregiver survey (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915) captured treatment experiences and preferences.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      GPB significantly reduced routine plasma ammonia levels by 21% (median 72 to 57 \u00b5mol\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011), with the proportion of patients above the local reference range dropping from 74% to 42%. Annualised HAC rates fell by 55% (2.2 to 1.0\/year), HAC-related hospitalisations by 27% (1.1 to 0.8\/year), and annualised HAC-related hospital stays by 24% (3.3 to 2.5 days\/year), though these did not reach statistical significance. Growth z-scores showed small, non-significant upward trends (+\u20090.2 for height and weight). GPB was well tolerated, with no treatment-related adverse events. All survey respondents (15\/15) preferred GPB over NaBz and NaPBA. 100% rated GPB equal or superior in controlling ammonia levels and being easier to adhere to, and 85% found it equal or better for palatability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GPB improved biochemical control and showed consistent trends toward reduced clinical burden in a real-world paediatric UCD cohort. Although some outcomes were not statistically significant, likely due to sample size and inter-individual variability, the magnitude and direction of change - supported by unanimous patient preference - highlight GPB\u2019s advantages. These findings support its use as a first-line or step-up therapy in paediatric UCDs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04216-6","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T14:44:17Z","timestamp":1769784257000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of glycerol phenylbutyrate on biochemistry and outcomes in paediatric patients with urea cycle disorders: a multicentre case series from Saudi Arabia"],"prefix":"10.1186","volume":"21","author":[{"given":"Rawan","family":"Hejazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thamer H.","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihab","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousra","family":"Naeim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamad","family":"Althiyab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"AlAnzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarar","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Alfadhel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruqaiah Saleh","family":"ALTassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhair N.","family":"Al-Hassnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1995-8465","authenticated-orcid":false,"given":"Moeenaldeen","family":"AlSayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"6","key":"4216_CR1","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/jimd.12100","volume":"42","author":"J H\u00e4berle","year":"2019","unstructured":"H\u00e4berle J, Burlina A, Chakrapani A, Dixon M, Karall D, Lindner M, et al. Suggested guidelines for the diagnosis and management of Urea cycle disorders: first revision. J Inherit Metab Dis. 2019;42(6):1192\u2013230.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"4216_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4103\/0256-4947.65254","volume":"30","author":"H Moammar","year":"2010","unstructured":"Moammar H, Cheriyan G, Mathew R, Al-Sannaa N. Incidence and patterns of inborn errors of metabolism in the Eastern Province of Saudi Arabia, 1983\u20132008. Ann Saudi Med. 2010;30(4):271\u20137.","journal-title":"Ann Saudi Med"},{"key":"4216_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2147\/TCRM.S93144","volume":"12","author":"M Alfadhel","year":"2016","unstructured":"Alfadhel M, Mutairi F, Al, Makhseed N, Jasmi F, Al, Al-Thihli K, Al-Jishi E, et al. Guidelines for acute management of hyperammonemia in the middle East region. Ther Clin Risk Manag. 2016;12:479\u201387.","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"4216_CR4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/jpc.13469","volume":"53","author":"M Alfadhel","year":"2017","unstructured":"Alfadhel M, Al Othaim A, Al Saif S, Al Mutairi F, Alsayed M, Rahbeeni Z, et al. Expanded newborn screening program in Saudi arabia: incidence of screened disorders. J Paediatr Child Health. 2017;53(6):585\u201391.","journal-title":"J Paediatr Child Health"},{"issue":"1","key":"4216_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13023-025-03647-x","volume":"20","author":"KM Stepien","year":"2025","unstructured":"Stepien KM, McSweeney M, Ochoa-Ferraro A, Vara R, Riley P, Smith M. Perspectives on long-term medical management of Urea cycle disorders: insights from a survey of UK healthcare professionals. Orphanet J Rare Dis. 2025;20(1):135.","journal-title":"Orphanet J Rare Dis"},{"key":"#cr-split#-4216_CR6.1","doi-asserted-by":"crossref","unstructured":"Smith W, Diaz GA, Lichter-Konecki U, Berry SA, Harding CO, McCandless SE et al. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate. J Pediatr [Internet]. 2013;162","DOI":"10.1016\/j.jpeds.2012.11.084"},{"key":"#cr-split#-4216_CR6.2","unstructured":"(6) [cited 2025 Jun 24]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23324524\/."},{"issue":"7","key":"4216_CR7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/jcph.92","volume":"53","author":"JPR Monteleone","year":"2013","unstructured":"Monteleone JPR, Mokhtarani M, Diaz GA, Rhead W, Lichter-Konecki U, Berry SA, et al. Population Pharmacokinetic modeling and dosing simulations of Nitrogen\u2010Scavenging compounds: disposition of glycerol phenylbutyrate and sodium phenylbutyrate in adult and pediatric patients with Urea cycle disorders. J Clin Pharmacol. 2013;53(7):699\u2013710.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"4216_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s41687-021-00387-x","volume":"5","author":"G Yeowell","year":"2021","unstructured":"Yeowell G, Burns DS, Fatoye F. The burden of Pharmacological treatment on health-related quality of life in people with a Urea cycle disorder: a qualitative study. J Patient Rep Outcomes. 2021;5(1):110.","journal-title":"J Patient Rep Outcomes"},{"key":"4216_CR9","doi-asserted-by":"crossref","unstructured":"Yeo M, Rehsi P, Dorman M, Grunewald S, Baruteau J, Chakrapani A et al. Clinical experience with glycerol phenylbutyrate in 20 patients with urea cycle disorders at a UK\u2009paediatric centre. JIMD Rep. 2023 Sep 23;64(5):317\u201326.","DOI":"10.1002\/jmd2.12386"},{"issue":"2","key":"4216_CR10","first-page":"137","volume":"63","author":"M Yeo","year":"2022","unstructured":"Yeo M, Rehsi P, Dorman M, Grunewald S, Baruteau J, Chakrapani A, et al. Direct replacement of oral sodium benzoate with glycerol phenylbutyrate in children with Urea cycle disorders. JIMD Rep. 2022;63(2):137\u201345.","journal-title":"JIMD Rep"},{"issue":"7","key":"4216_CR11","first-page":"708","volume":"20","author":"SCS Nagamani","year":"2018","unstructured":"Nagamani SCS, Agarwal U, Tam A, Azamian M, McMeans A, Didelija IC, et al. A randomized trial to study the comparative efficacy of phenylbutyrate and benzoate on nitrogen excretion and ureagenesis in healthy volunteers. Genet Sci. 2018;20(7):708\u201316.","journal-title":"Genet Sci"},{"issue":"1","key":"4216_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ymgme.2014.02.007","volume":"112","author":"SA Berry","year":"2014","unstructured":"Berry SA, Lichter-Konecki U, Diaz GA, McCandless SE, Rhead W, Smith W, et al. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes. Mol Genet Metab. 2014;112(1):17\u201324.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"4216_CR13","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1002\/hep.26058","volume":"57","author":"GA Diaz","year":"2013","unstructured":"Diaz GA, Krivitzky LS, Mokhtarani M, Rhead W, Bartley J, Feigenbaum A, et al. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. Hepatology. 2013;57(6):2171\u20139.","journal-title":"Hepatology"},{"key":"4216_CR14","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Hern\u00e1ndez E, Quijada-Fraile P, Correcher P, Meavilla S, S\u00e1nchez-Pintos P, de Las Heras Montero J et al. Switching to glycerol phenylbutyrate in 48 patients with Urea cycle disorders: clinical experience in Spain. J Clin Med. 2022;11(17):5045.","DOI":"10.3390\/jcm11175045"},{"issue":"22","key":"4216_CR15","first-page":"11131","volume":"27","author":"M Sacchini","year":"2023","unstructured":"Sacchini M, Procopio E, Pochiero F, Scaturro G, Daniotti M, Donati MA. Transition to glycerol phenylbutyrate for the management of Urea cycle disorders: clinical experiences. Eur Rev Med Pharmacol Sci. 2023;27(22):11131\u201342.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"4216_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ymgme.2018.09.001","volume":"125","author":"SA Berry","year":"2018","unstructured":"Berry SA, Vockley J, Vinks AA, Dong M, Diaz GA, McCandless SE, et al. Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2 months to 2 years of age with urea cycle disorders. Mol Genet Metab. 2018;125(3):251\u20137.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"4216_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ymgme.2010.03.014","volume":"100","author":"B Lee","year":"2010","unstructured":"Lee B, Rhead W, Diaz GA, Scharschmidt BF, Mian A, Shchelochkov O, et al. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: Safety, pharmacokinetics and ammonia control. Mol Genet Metab. 2010;100(3):221\u20138.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"4216_CR18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ymgme.2019.07.004","volume":"127","author":"GA Diaz","year":"2019","unstructured":"Diaz GA, Schulze A, Longo N, Rhead W, Feigenbaum A, Wong D, et al. Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients. Mol Genet Metab. 2019;127(4):336\u201345.","journal-title":"Mol Genet Metab"},{"issue":"12","key":"4216_CR19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1080\/21678707.2017.1405807","volume":"5","author":"N Longo","year":"2017","unstructured":"Longo N, Holt RJ. Glycerol phenylbutyrate for the maintenance treatment of patients with deficiencies in enzymes of the urea cycle. Expert Opin Orphan Drugs. 2017;5(12):999\u20131010.","journal-title":"Expert Opin Orphan Drugs"},{"key":"4216_CR20","first-page":"43","volume":"8","author":"OA Shchelochkov","year":"2016","unstructured":"Shchelochkov OA, Dickinson K, Scharschmidt BF, Lee B, Marino M, Le Mons C. Barriers to drug adherence in the treatment of urea cycle disorders: assessment of patient, caregiver and provider perspectives. Mol Genet Metab Rep. 2016;8:43\u20137.","journal-title":"Mol Genet Metab Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04216-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04216-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04216-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:25:25Z","timestamp":1781630725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04216-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4216"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04216-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"30 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"King Faisal Specialist Hospital and Research Centre institutional review board (IRB) approved this study (RAC # 2231012) and publication (# 2255119). Clinical trial number: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent was obtained from all the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}